While no serious adverse effects have been reported in patients with venous thrombosis treated systemically with mesoglycan [118,119], chronic overstimulation of VEGF-A production could lead to unwanted angiogenesis and tumor growth [16,19,120]. This evidence concerns the gene VEGFA and neoplasm.